- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05803382
Testando a adição de uma droga anticancerígena, ZEN003694, ao tratamento quimioterápico usual (capecitabina) para cânceres metastáticos ou irressecáveis
Ensaio de Fase I de ZEN003694 (ZEN-3694) em Combinação com Capecitabina em Pacientes com Tumores Sólidos
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and that it has progressed on previous standard treatment. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that over produce BET protein. Capecitabine is in a class of medications called antimetabolites. It is taken up by cancer cells and breaks down into fluorouracil, a substance that kills cancer cells. Giving ZEN003694 in combination with capecitabine may be safe in treating patients with metastatic or unresectable solid tumors.
Visão geral do estudo
Status
Condições
Descrição detalhada
PRIMARY OBJECTIVE:
I. To determine the safety and tolerability, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of BET bromodomain inhibitor ZEN-3694 (ZEN003694 [ZEN-3694]) in combination with capecitabine in patients with solid tumors.
SECONDARY OBJECTIVES:
I. To observe and record anti-tumor activity of ZEN003694 (ZEN-3694) in combination with capecitabine.
II. To determine the pharmacokinetics (PK) of ZEN003694 (ZEN-3694) in combination with capecitabine.
III. To determine the pharmacodynamics (PD) of ZEN003694 (ZEN-3694) in combination with capecitabine (death receptor 5 [DR5] dynamics and apoptosis).
IV. To identify molecular subpopulations particularly sensitized to bromodomain and extra-terminal motif inhibitor (BETi) and capecitabine.
OUTLINE: This is a dose-escalation study of ZEN003694 and capecitabine, followed by a dose-expansion study.
Patients receive ZEN003694 orally (PO) once daily (QD) and capecitabine PO twice daily (BID) 2 weeks on, 1 week off during each treatment cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. NOTE: Patients do not receive ZEN003694 on day 1 of cycle 1. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI), positron emission tomography (PET)/CT, and collection of blood samples throughout the trial. Patients may also undergo biopsies during screening and while on the study.
After completion of study treatment, patients are followed up for safety 30 days after the last dose, and then every 3 months for 12 months.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
California
-
Irvine, California, Estados Unidos, 92612
- Recrutamento
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Contato:
- Site Public Contact
- Número de telefone: 877-827-8839
- E-mail: ucstudy@uci.edu
-
Investigador principal:
- Fa-Chyi Lee
-
Orange, California, Estados Unidos, 92868
- Recrutamento
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 877-827-8839
- E-mail: ucstudy@uci.edu
-
Investigador principal:
- Fa-Chyi Lee
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32610
- Recrutamento
- UF Health Cancer Institute - Gainesville
-
Contato:
- Site Public Contact
- Número de telefone: 352-273-8010
- E-mail: cancer-center@ufl.edu
-
Investigador principal:
- Thomas J. George
-
-
Illinois
-
Shiloh, Illinois, Estados Unidos, 62269
- Ativo, não recrutando
- Memorial Hospital East
-
-
Kansas
-
Fairway, Kansas, Estados Unidos, 66205
- Recrutamento
- University of Kansas Clinical Research Center
-
Contato:
- Site Public Contact
- Número de telefone: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Investigador principal:
- Joaquina C. Baranda
-
Kansas City, Kansas, Estados Unidos, 66160
- Recrutamento
- University of Kansas Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Investigador principal:
- Joaquina C. Baranda
-
Westwood, Kansas, Estados Unidos, 66205
- Recrutamento
- University of Kansas Hospital-Westwood Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Investigador principal:
- Joaquina C. Baranda
-
-
Missouri
-
City of Saint Peters, Missouri, Estados Unidos, 63376
- Ativo, não recrutando
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Estados Unidos, 63141
- Ativo, não recrutando
- Siteman Cancer Center at West County Hospital
-
St Louis, Missouri, Estados Unidos, 63110
- Ativo, não recrutando
- Washington University School of Medicine
-
St Louis, Missouri, Estados Unidos, 63129
- Ativo, não recrutando
- Siteman Cancer Center-South County
-
St Louis, Missouri, Estados Unidos, 63136
- Ativo, não recrutando
- Siteman Cancer Center at Christian Hospital
-
-
New York
-
New York, New York, Estados Unidos, 10032
- Recrutamento
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
Investigador principal:
- Ryan Moy
-
Contato:
- Site Public Contact
- Número de telefone: 212-342-5162
- E-mail: cancerclinicaltrials@cumc.columbia.edu
-
The Bronx, New York, Estados Unidos, 10461
- Recrutamento
- Montefiore Medical Center-Einstein Campus
-
Contato:
- Site Public Contact
- Número de telefone: 718-379-6866
- E-mail: eskwak@montefiore.org
-
Investigador principal:
- Chaoyuan Kuang
-
The Bronx, New York, Estados Unidos, 10467
- Recrutamento
- Montefiore Medical Center - Moses Campus
-
Contato:
- Site Public Contact
- Número de telefone: 718-379-6866
- E-mail: eskwak@montefiore.org
-
Investigador principal:
- Chaoyuan Kuang
-
The Bronx, New York, Estados Unidos, 10461
- Recrutamento
- Montefiore Medical Center-Weiler Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 718-379-6866
- E-mail: eskwak@montefiore.org
-
Investigador principal:
- Chaoyuan Kuang
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- Recrutamento
- University of Cincinnati Cancer Center-UC Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 513-584-7698
- E-mail: cancer@uchealth.com
-
Investigador principal:
- Davendra P. Sohal
-
West Chester, Ohio, Estados Unidos, 45069
- Recrutamento
- University of Cincinnati Cancer Center-West Chester
-
Contato:
- Site Public Contact
- Número de telefone: 513-584-7698
- E-mail: cancer@uchealth.com
-
Investigador principal:
- Davendra P. Sohal
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Recrutamento
- University of Oklahoma Health Sciences Center
-
Contato:
- Site Public Contact
- Número de telefone: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Investigador principal:
- Susanna V. Ulahannan
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- Recrutamento
- UPMC Hillman Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 412-647-8073
-
Investigador principal:
- Anwaar Saeed
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- Recrutamento
- Vanderbilt University/Ingram Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-811-8480
-
Investigador principal:
- Thatcher R. Heumann
-
Nashville, Tennessee, Estados Unidos, 37204
- Recrutamento
- Vanderbilt Breast Center at One Hundred Oaks
-
Contato:
- Site Public Contact
- Número de telefone: 800-811-8480
-
Investigador principal:
- Thatcher R. Heumann
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Dose Escalation additional criteria: Patients must have histologically confirmed cancer that is metastatic or unresectable and must have progressed on standard therapies which would have included fluorouracil (5-FU) or capecitabine
- Dose Escalation additional criteria specifically for colorectal cancer (CRC) patients: Willingness and ability to undergo a pre-treatment biopsy
- Dose Expansion additional criteria: Patients must have histologically confirmed CRC that is metastatic or unresectable and must have progressed on standard therapies which would have included 5-FU or capecitabine
- Dose Expansion additional criteria: Willingness and ability to undergo pre- and on- treatment biopsies
- Patients must have measurable disease
- Age >= 18 years. Because no dosing or adverse event data are currently available on the use of ZEN003694 (ZEN-3694) in combination with capecitabine in patients < 18 years of age, children are excluded from this study
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (Karnofsky >= 60%)
- Availability of archival tumor tissue at the time of patient enrollment for molecular profiling studies
- Prior to study dosing, previous systemic therapy must have been completed for at least five half-lives or 2 weeks, whichever is shorter
- Absolute neutrophil count >= 1,000/mcL
- Platelets >= 100,000/mcL
- Total bilirubin =< 1.5 institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN
- Glomerular filtration rate (GFR) >= 50 mL/min/1.73 m^2
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- Patients should be New York Heart Association Functional Classification of class 2B or better
- The effects of ZEN003694 (ZEN-3694) and capecitabine on the developing human fetus are unknown. For this reason and because BET inhibitors as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Women of child-bearing potential and men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of ZEN003694 (ZEN-3694) and capecitabine administration
- Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants
Exclusion Criteria:
- Previous treatment with BET inhibitors
- History of inability to tolerate capecitabine at the projected treatment dose on this trial
- Use of oral Factor Xa inhibitors (i.e., rivaroxaban, apixaban, betrixaban, edoxaban otamixaban, letaxaban, eribaxaban) and Factor IIa inhibitors (i.e., dabigatran). Low molecular weight heparin is allowed
- Treatment for HIV, hepatitis B or hepatitis C only if this interferes with the current treatment (e.g. through drug-drug interactions)
- Gastrointestinal pathology or history that adversely impacts the ability to take or absorb oral medication
- Hepatic tumor burden > 30% or peritoneal carcinomatosis
- Untreated/uncontrolled central nervous system (CNS) disease
- Known dihydropyrimidine dehydrogenase (DPD) deficiency
- Severe intercurrent illness or comorbidity
- Inability to comply with the protocol and/or not willing or who will not be available for follow-up assessments
- Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia and neuropathy up to and including grade 2
- Patients who are receiving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZEN003694 (ZEN-3694) or other agents used in study
- Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible. Strong inhibitors of CYP3A4 must be discontinued at least 7 days, and inducers 14 days prior to the first dose of ZEN003694 and capecitabine. Substrates of CYP1A2 with narrow therapeutic window must be avoided while taking ZEN003694
- Pregnant women are excluded from this study because ZEN003694 (ZEN-3694) is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ZEN003694 (ZEN-3694), breastfeeding should be discontinued if the mother is treated with ZEN003694 (ZEN-3694). These potential risks may also apply to other agents used in this study
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Treatment (ZEN003694, capecitabine)
Patients receive ZEN003694 PO QD and capecitabine PO BID 2 weeks on, 1 week off during each treatment cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. NOTE: Patients do not receive ZEN003694 on day 1 of cycle 1. Patients undergo CT or MRI, PET/CT, and collection of blood samples throughout the trial. Patients may also undergo biopsies during screening and while on the study. |
Undergo MRI
Outros nomes:
Undergo biopsy
Outros nomes:
Undergo collection of blood samples
Outros nomes:
Undergo PET/CT
Outros nomes:
Given PO
Outros nomes:
Given PO
Outros nomes:
Undergo CT and PET/CT
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of adverse events
Prazo: Up to 30 days after last dose
|
Adverse events and serious adverse events will be tabulated for each dose levels. As per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, the term toxicity is defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment. The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. |
Up to 30 days after last dose
|
|
Maximum tolerated dose (MTD)
Prazo: During the first cycle of therapy (Cycles = 21 days)
|
Defined as the highest dose level with no more than 1/6 dose-limiting toxicity. Dose level 4 was selected as the MTD. |
During the first cycle of therapy (Cycles = 21 days)
|
|
Recommended phase 2 dose (RP2D)
Prazo: Up to 30 days after last dose
|
Dose level 4 was selected as the RP2D. |
Up to 30 days after last dose
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Anti-tumor activity of ZEN003694 (ZEN-3694) in combination with capecitabine
Prazo: Up to 12 months
|
Treatment response will be assessed for all patients based on Response Evaluation Criteria in Solid Tumors version 1.1: complete response (CR), partial response (PR), stable disease (SD), and progression of disease (PD). Clinical benefit rate is defined as the addition of CR, PR and SD. |
Up to 12 months
|
|
Progression free survival (PFS)
Prazo: Up to 12 months
|
PFS will be estimated by the Kaplan-Meier method, along with 95% confidence regions. |
Up to 12 months
|
|
Objective response rate (ORR)
Prazo: Up to 12 months
|
Defined as the addition of CR and PR. The probability of ORR and clinical benefit rate will be estimated with exact 95% binomial confidence intervals. |
Up to 12 months
|
|
Pharmacokinetics (PK) of ZEN003694 (ZEN-3694) in combination with capecitabine
Prazo: Up to 12 months
|
Will determine the PK of ZEN003694 (ZEN-3694) in combination with capecitabine. Capecitabine PK will be evaluated in the absence and presence of ZEN003694 (ZEN-3694) and Cmax and area under curve (AUC) will be compared with a paired test. ZEN003694 (ZEN-3694) PK will be evaluated in the presence of capecitabine and Cmax and AUC will be compared descriptively with historical data. |
Up to 12 months
|
|
Pharmacodynamics (PD) of ZEN003694 (ZEN-3694) in combination with capecitabine
Prazo: Up to 12 months
|
Will determine PD of ZEN003694 (ZEN-3694) in combination with capecitabine. Ribonucleic acid sequencing of death receptor 5 (DR5). DR5 is expected to be increased by the combination ZEN003694 (ZEN-3694) in combination with capecitabine. Pre-post comparisons will be made within patients enrolled on the expansion cohort using a non-parametric paired test, at a significance level (alpha) of 0.05. Apoptosis by Pharmacodynamic Assay Development and Implementation Section (PADIS) lab. Panel 3 is priority, but other panels will be evaluated with remaining lysate. Apoptosis is expected to be increased by the combination ZEN003694 (ZEN-3694) in combination with capecitabine. Pre-post comparisons will be made within patients enrolled on the expansion cohort using a non-parametric paired test, at a significance level (alpha) of 0.05. |
Up to 12 months
|
|
Molecular subpopulations particularly sensitized to BETi and capecitabine
Prazo: Up to 12 months
|
Will identify molecular subpopulations particularly sensitized to BETi and capecitabine. Based on WES of archival tissue, we will evaluate descriptively any mutations in genes relevant to DNA damage repair, signaling and (fluoropyrimidine) metabolism, any relations with peculiar response and/or toxicity. |
Up to 12 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Anwaar Saeed, University of Pittsburgh Cancer Institute LAO
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Processos Patológicos
- Neoplasias por local
- Neoplasias
- Doenças Intestinais
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças do aparelho digestivo
- Doenças Gastrointestinais
- Neoplasias Intestinais
- Doenças retais
- Doenças do cólon
- Processos Neoplásicos
- Condições Patológicas, Sinais e Sintomas
- Neoplasias Colorretais
- Neoplasia Metástase
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Técnicas de investigação
- Técnicas de laboratório clínico
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Procedimentos cirúrgicos, operatórios
- Técnicas citológicas
- Ácidos nucleicos, nucleotídeos e nucleosídeos
- Citodiagnóstico
- Desoxicitidina
- Citidina
- Nucleosídeos de pirimidina
- Pirimidinas
- Técnicas de diagnóstico, cirúrgico
- Técnicas de química, analíticas
- Análise de espectro
- Nucleosídeos
- Uracil
- Pirimidinonas
- Desoxirribonucleosídeos
- Fluorouracil
- Capecitabina
- Biópsia
- Manipulação de amostras
- Espectroscopia de ressonância magnética
Outros números de identificação do estudo
- NCI-2023-02652
- UM1CA186690 (Concessão/Contrato do NIH dos EUA)
- 10579 (Outro identificador: CTEP)
- NCI-2023-02652 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- HCC 23-096
- 10579 (Outro identificador: UPMC Hillman Cancer Center LAO)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .